# The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus

> **NCT06203275** · PHASE3 · UNKNOWN · sponsor: **aya ramadan ashmawy sarhan** · enrollment: 44 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Paroxetine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06203275
- **Lead sponsor:** aya ramadan ashmawy sarhan
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01
- **Primary completion:** 2025-01
- **Final completion:** 2026-01
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2024-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06203275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06203275, "The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06203275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*